Today's Vision Fuqua

05/21/2026

What is Stargardt Disease?

Stargardt Disease is an Inherited Retinal Disease (IRD) that causes damage to the macula - the area that is responsible for straight ahead vision.

As part of Stargardt Disease Week, learn more about signs and symptoms: PreventBlindness.org/Stargardt-Disease.

This year’s Inherited Retinal Disease and Genetic Testing Month/Stargardt Disease Week are sponsored by Belite Bio and Blue Rock.

05/20/2026

Congratulations to all the new Grads!! We are so proud of you all.

05/19/2026

Good Morning! We are open today from 9am till 5pm. Let us know if you need a Saturday appointment. There are just a few left.

05/18/2026

Happy Monday! We will now be open for select Saturdays throughout the summer. Call for availability as appointments tend to fill quickly.

09/19/2025

A recent study has uncovered a new type of stem cell in the human eye that could pave the way for restoring lost vision in people with retinal diseases. These stem cells have the remarkable ability to generate healthy retinal cells, offering hope for conditions like macular degeneration and retinitis pigmentosa, which currently have limited treatment options.

Researchers believe that by harnessing these stem cells, it may be possible to replace damaged retinal tissue and restore sight in patients who have experienced significant vision loss. Early laboratory tests show promising results, with the cells successfully integrating into retinal tissue and supporting the regeneration of critical visual structures.

This discovery marks a major milestone in regenerative medicine and ophthalmology, opening the door to innovative therapies that could prevent blindness and dramatically improve quality of life for millions of people worldwide. Further research and clinical trials are underway to ensure safety and effectiveness, bringing the possibility of vision restoration closer to reality than ever before.

08/28/2025

https://scitechdaily.com/first-ever-treatment-for-rare-eye-disease-wins-fda-approval-after-landmark-trials/?fbclid=IwVERDUAMcuOJleHRuA2FlbQIxMAABHj-VLncRr_tgk2hjlldMYnxe7IkxAyq6m2pVS7EcSj0o2qmdyyzpFUTx_bVg_aem_JqrVCc6tzLG-WiVJIPl_qA

Phase 3 clinical trial results from Scripps Research and its collaborators supported FDA approval of ENCELTO, the first cell-based treatment for the neurodegenerative retinal disease known as MacTel. For individuals with macular telangiectasia type 2 (MacTel), a rare retinal disease that steadily

05/31/2025

https://www.facebook.com/share/v/16GDZfbetK/

05/04/2025

Happy May the 4th!!